The adenosine class of heterotrimeric guanine nucleotidebinding protein (G protein)-coupled receptors (GPCRs) mediates the important role of extracellular adenosine in many physiological processes and is antagonized by caffeine. We have determined the crystal structure of the human A 2A adenosine receptor, in complex with a highaffinity subtype-selective antagonist, ZM241385, to 2.6 angstrom resolution. Four disulfide bridges in the extracellular domain, combined with a subtle repacking of the transmembrane helices relative to the adrenergic and rhodopsin receptor structures, define a pocket distinct from that of other structurally determined GPCRs. The arrangement allows for the binding of the antagonist in an extended conformation, perpendicular to the membrane plane. The binding site highlights an integral role for the extracellular loops, together with the helical core, in ligand recognition by this class of GPCRs and suggests a role for ZM241385 in restricting the movement of a tryptophan residue important in the activation mechanism of the class A receptors.
Extracellular adenosine plays an important role in physiology and initiates most of its effects through the activation of four guanine nucleotide binding protein (G protein) coupled receptor (GPCR) subtypes, A 1 , A 2A , A 2B and A 3 (1, 2) . Each of these four receptors plays an essential role in responding to adenosine in the central nervous system (3, 4) regulating pain (5) , cerebral blood flow (6) , basal ganglia functions (7), respiration (8) and sleep (9) . These receptor subtypes are primarily coupled to the cAMP second messenger system and each has its own unique pharmacological profile. The A 2A adenosine subtype is linked to G s and G olf proteins and upon receptor activation, the intracellular levels of cAMP increase. At least three of the four adenosine receptor subtypes (A 1 , A 2A and A 2B ) are blocked by naturally occurring methylxanthines, such as caffeine, with modest affinity. Interestingly, strong epidemiological evidence suggests that coffee drinkers have a lower risk of Parkinson's disease (10) . This effect has been linked to caffeine's interaction with the A 2A adenosine receptor, which controls locomotor behavior in basal ganglia together with dopamine D 2 and metabotropic glutamate mGluR receptors (11, 12) . Development of more selective compounds for adenosine receptor subtypes could provide a class of therapeutics for treating numerous human maladies, such as pain (5), Parkinson's disease (7, 13) , Huntington disease (14) , asthma (15) , seizures (16) and many other neurological disorders (14, 17) .
We have determined the crystal structure of the human A 2A adenosine receptor in complex with the subtype selective high affinity antagonist (4-(2- (18, 19) . The basis for this compound's selectivity over the adenosine A 1 and A 3 receptors can now be analyzed in the context of its molecular interactions with the A 2A receptor along with previously reported mutagenesis data. With an additional human GPCR structure, it is now possible to extend the analysis of structural differences as they pertain to receptor pharmacology, ligand recognition and receptor activation across the members of the class A receptor family.
Structure determination. GPCRs possess numerous thermodynamic conformations (20, 21) , implying an inherent structural flexibility (22) (23) (24) . This flexibility manifests itself as thermal instability upon detergent extraction from lipid membranes and is one of the primary challenges in generating crystals of GPCRs (25, 26) . In order to overcome this obstacle with the human A 2A adenosine receptor, we applied the T4L fusion strategy (24, 27, 28) , where most of the third cytoplasmic loop (Leu209 5.70 -Ala221 6.23 ) was replaced with lysozyme from T4 bacteriophage and the carboxyl-terminal tail (Ala317 -Ser412) was deleted to improve the likelihood of crystallization. The resulting recombinant construct (A 2A -T4L-ΔC) was further stabilized during purification with (i) sodium chloride, which has a beneficial effect on adenosine receptor stability, (ii) a saturating concentration of the
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Veli-Pekka Jaakola, 1 nonspecific adenosine receptor antagonist theophylline (ZM241385 was exchanged from theophylline in the last purification step) and (iii) including cholesteryl hemisuccinate throughout the purification. Purified A 2A -T4L-ΔC bound to ZM241385 was crystallized using the in meso crystallization methodology where the lipid phase consisted of a mixture of monoolein and cholesterol (29) . Diffraction data from thirteen of the best crystals were combined to yield a 2.6 Å dataset (Table 1) . Phases were obtained by molecular replacement using the coordinates of the β 2 -adrenergic receptor (β 2 AR) fused to T4-lysozyme (PDB accession number, 2RH1). The final refined model includes residues Ile3 to Gln310 of the human A 2A adenosine receptor, residues 2 to 161 of T4-lysozyme, five lipid hydrocarbon chains modeled as stearic acid, eight sulfate ions and the antagonist ZM241385 bound in the ligand binding cavity (Fig. 1) . The experimental electron density for the amino (Met1 -Pro2) and carboxyl (Glu311 -Ala316) termini did not support modeling of these regions. In addition, the tip of second extracellular loop (Gln148 -Ser156) was not modeled due to weak experimental electron density. Although cholesterol does have a significant stabilizing effect on the A 2A adenosine receptor and was included in the crystallization trials, in contrast to the β 2 -adrenergic receptor structure which has cholesterol bound in a pocket referred to as the cholesterol consensus motif (30) , the A 2A adenosine receptor structure has phospholipid bound in the same area. (24) ; however, unlike β 2 AR, the A 2A -WT has no associated basal activity (G protein signalling in the absence of agonist). The inclusion of a high concentration of sodium chloride in the assay medium induced a substantial decrease in the agonist affinity for all of the tested constructs (Fig. 2B ) but did not appreciably affect antagonist affinity. Interestingly, pK i values for the agonist in the presence of sodium chloride were virtually identical for all constructs tested (table S2) suggesting that sodium chloride induced a shift in receptor equilibrium to an inactive state (32). In addition, sodium chloride induced a 10 °C increase in thermal stability for A 2A -T4L-ΔC solubilized in n-Dodecyl-β-Dmaltoside ( fig. S3 ). Thus, radioligand binding experiments support the conclusion that the construct used for crystallization is a functional receptor with an increased affinity for agonist, and wild-type affinity for antagonist.
Architecture of the human A 2A adenosine receptor. The residues constituting the transmembrane α-helices are: Gly5 has been replaced by 160 residues from T4 lysozyme (see fig.  S1 ). Additionally, The N-linked glycan associated with Asn154 4.75 has been removed enzymatically to improve crystallization. Our crystallographic model of A 2A -T4L-ΔC bound to ZM241385 reveals three features distinct from the previously reported GPCR structures. First, the organization of the extracellular loops is markedly different from β 1 AR, β 2 AR and bovine/squid rhodopsins (23, 24, 30, (35) (36) (37) . Secondly, ZM241385 binds in an extended conformation perpendicular to the plane of the membrane and co-linear with transmembrane helix VII interacting with both ECL2 and ECL3. This is somewhat incongruous with earlier molecular modeling studies based on β 2 AR and rhodopsin homology models where ZM241385 and other antagonists were docked into a binding site emulating that of β 2 AR and rhodopsin (for examples see (38, 39) , and references therein). Finally, a subtle divergence in the helical positions and orientations relative to rhodopsin and β 2 AR redefines the antagonist binding cavity so that it is located closer to helices VI and VII and allowing only limited interactions with helices III and V.
Helical position and binding pocket diversity. Among the class A GPCRs, the sequence identity is highest within the α-helical transmembrane regions and ranges from 20-50% (40, 41) . Not surprisingly, the helical arrangement is similar among the human β 2 AR, turkey β 1 AR and squid/bovine rhodopsins structures determined to date. However, shifts in the relative positions of the various helices results in a root mean square deviation (RMSDs) between 2.0 to 2.5 Å (depending on how the alignment is carried out and which structures are being compared) that has structural, and biochemical implications. Most of the structural divergence arises in the extracellular portions of helices I, II, III and V, where the variation in the positions of helices II, III and V appears to redefine the location of the ligand binding pocket (42) . However, comparisons between ground-state rhodopsin bound to retinal and β 2 AR bound to carazolol show minimal differences as the relative helical shifts are smaller (Fig. 3 , A and B) (27) . The position of the retinal and carazolol binding pocket is very similar and making most contact with helices III, V, VI (Figs. 3A and 4). The binding pocket of the A 2A adenosine receptor is shifted closer to helices VI and VII which contribute the majority of the binding interactions associated with helical regions, as judged by occluded surface area calculations (43, 44) (Fig. 3B and Fig. 4) . A concomitant shift of helices II and V (7 Å and 3 Å, respectively) toward the binding pocket, and a lateral shift of helix III toward helix V by 3 Å, compensates for the absence of ligand interactions in this region by increasing protein packing interactions (Fig.  3, A and B) .
Conformational equilibrium and receptor activation. A common feature of the class A GPCRs is the presence of a tryptophan residue (at position 6.48) on helix VI whose rotameric position is thought to control the equilibrium between the active and inactive states of each receptor (45) . Based on the position of retinal in the rhodopsin structure it was proposed that ligand interactions with this key residue could modulate receptor equilibrium (46) . Interestingly, the contact area between the ligand and the "toggle switch" tryptophan residue at position 6.48 varies considerably among the solved receptor structures. For instance, rhodopsin and β 2 AR have a similar binding mode as noted; however, retinal in rhodopsin has a contact area of 36 Å 2 , whereas carazolol bound to β 2 AR lacks any direct contact with Trp286 6.48 (27) .
Ground-state rhodopsin has virtually no basal activity, whereas β 2 AR has a relatively high basal activity which is suppressed somewhat by carazolol as an inverse agonist (23, 47) . The observed increase in contact area may have direct implications for inverse agonist efficacy or suppressed basal activity by limiting the range of motion of the "toggle switch" tryptophan. 5A ). Similar hydrogen bonding interactions were reported in the turkey β 1 AR structure (37), but not in any of the β 2 AR structures where Asp130 3.49 forms a hydrogen bond with Ser143 3.62 although there is a tyrosine at the 3.60 position (Fig. 5 , B and C) (23, 24, 30) . This discrepancy is caused by a short helical section in the ICL2 loop of both β 1 AR and the A 2A adenosine receptor that is not present in any of the β 2 AR structures (Fig. 5) . It has been proposed that ICL2 serves as a control switch facilitating G protein activation through a select set of interactions (50) . Interestingly the basal activity profile among the β 1 AR, β 2 AR and the A 2A adenosine receptors correlates with the presence of this short helix in ICL2 and the presence of hydrogen bonding interactions between tyrosine at position 3.60 in ICL2 and Asp at position 3.49. In β 1 AR and A 2A adenosine receptor, both of which have low basal activity, this interaction is present (51, 52) . In contrast, β 2 AR exhibits high basal activity and lacks helical structure within its ICL2 resulting in altered interactions with the DRY motif (51). Instead of participating in an 'ionic lock' as in rhodopsin, the arginine residue in the D/ERY motif may play a role in stabilizing the deprotonated state of the adjacent aspartate or glutamate residue, which would strengthen the polar interactions between the D/ERY motif and both ICL2, and helix II. This set of interactions may have direct implications in G protein activation (48) . Extracellular loops mediation of ligand entry and binding. The extracellular surface properties of the A 2A adenosine receptor is largely dictated by its second extracellular loop (ECL2), which is considerably different from that of β 1 AR, β 2 AR and rhodopsin ( Fig. 1 and Fig. 4 ). The ECL2 of the A 2A adenosine receptor lacks the prominent secondary structural elements, such as β-sheet and α-helix, which were observed in the rhodopsin and β-adrenergic receptors, respectively. Instead, the ECL2 of the A 2A adenosine receptor is mainly a spatially constrained random coil possessing three disulfide linkages with ECL1 (Fig. 4C) fig. S1 ) are critical for expression due to a complete loss of radiolabeled antagonist binding in the absence of this disulfide bond. Analysis of the ligand binding cavity. To date, structural and biophysical data on the class A GPCRs with diffusible ligands has been dominated by the biogenic amine receptors, such as the adrenergic, dopamine, and serotonin families. These amine ligands are all positively charged at physiologic pH and are known to interact with a key negatively charged aspartate residue (Asp 3.32 ) on helix III. Indeed, in all three of the available β-adrenergic structures, each co-crystallized ligand interacts with this residue and binds in a pocket quite similar to that of retinal in rhodopsin. Analysis of the binding sites of the three available GPCR structures indicates two possibilities for the other members of the class A family: i) other ligands will bind in a spatially similar binding site, with the ligand specificity dictated by sequence differences within the binding pocket, or ii) ligands for other receptors may bind in a completely different fashion interacting with other positions on the receptor. In contrast to the β-adrenergic ligands and retinal, ZM241385 occupies a significantly different position in the transmembrane network (Fig. 4) where its orientation is almost perpendicular to the membrane plane (Figs. 4C and 6 ). The bicyclic triazolotriazine core of ZM241385 is anchored by an aromatic stacking interaction with Phe168 5.29 , an aliphatic hydrophobic interaction with Ile274 7.39 and a hydrogen bonding interaction with Asn253 6.55 ( Fig. 6 ). Adjacent to Phe168 5.29 a polar residue (Glu169 5.30 )
interacts with the exocyclic amino group (N15 atom) linked to the bicyclic core of ZM241385 (Fig. 6B) . Mutation of Glu169 5.30 to alanine reduces the affinity for both antagonists and agonists and causes a 1000-fold reduction in agonist efficacy (54) . However, mutating this position to glutamine did not have a substantial impact on antagonist binding affinity, suggesting hydrogen bonding as the predominant means of interacting with N15 of ZM241385 as opposed to Coulombic interactions (Fig. 6B) . Early studies indicate that mutation of Asn253 6.55 to alanine, which would disrupt an important polar contact with the exocyclic N15 atom of ZM241385, results in a complete loss of both agonist and antagonist binding (55 to alanine completely abolishes ligand binding, whereas mutation to phenylalanine or tyrosine residues modestly affects agonist binding but not antagonist binding (55, 58) ; replacement with an asparagine slightly increases ligand affinity (58) . The furan ring is approximately 3 Å away from the highly conserved Trp246 6.48 an important residue in receptor activation as discussed above (59). We speculate that the hydrophobic interactions between ZM241385's furan ring and this residue will hinder the structural rearrangements necessary for activation, constraining the receptor in an inactive state. The A 2A adenosine ligand bound structure suggests that there is no general, family conserved receptor binding pocket in which selectivity is achieved through different amino acid side chains. Rather, the pocket itself can vary in position and orientation, yielding more opportunity for receptor diversity and ligand selectivity. Perhaps as a result of this shift the empirically determined positions of the substituents (phenyl/furanyl) extending from the aromatic core of ZM241385 deviate significantly from what was suggested in molecular modeling studies in which the ligand binding site of retinal and/or beta-blockers was used as the starting point (38, 39) . The position of these substituents can be seen as the rationale for A 2A receptor selectivity and this may help in the design of new chemical entities with increased selectivity for this important drug target.
replaced with the lysozyme from T4 bacteriophage and the full carboxy terminus intact (Ala317 to Ser412). A 2A -WT refers to the wild-type construct without the T4 lysozyme. All constructs have a FLAG purification tag in the amino terminus and ten histidine residues in the carboxy terminus. 32. Z. G. Gao, A. P. Ijzerman, Biochem Pharmacol 60, 669 (2000). 33. Amino-acid numbering based on human Adenosine A 2a primary sequence (accession number P29274).; NOTE: In addition to numbering residue positions in the primary amino acid sequence, the residues have numbers in superscripts (X.YY) that indicate their position in each transmembrane helix (X, helix number, from 1 to 8)), relative to the most conserved reference residue in that helix (YY). This residue is arbitrarily assigned the number 50, numbers decreasing towards N-terminus and increasing towards C-terminus However, the numbering is not used in loop regions beyond residues X.20 and/or X.80 or T4L 34. In this crystal form, the crystallographic contacts are mostly driven by the T4L protein where receptor-tolysozyme and lysozyme-to-lysozyme mainly form the lattice contacts. A relatively large receptor-to-receptor crystallographic interface (~520 Å 2 ) forms anti-parallel receptor dimers (supplementary figure). The total surface interface between receptor and T4L moieties is ~1300 Å 2 ,
whereas lysozyme-to-lysozyme is ~200 Å 2 . The largest contact interface(~500 Å 2 ) between receptor and T4L is non-crystallographic, and is located in the cytoplasmic site, where receptor is fused to the T4L,. The other receptor-to-lysozyme surface interfaces are crystallographic (260 Å 2 ). In comparison to the previously solved β 2 AR-T4L fusion proteins, the T4L domain is significantly tilted from the membrane plane, and creates more surface interactions than seen in human β 2 AR-T4L contructs that were solved in different space groups. 
